PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1876573
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1876573
Drug Repurposing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
The Global Drug Repurposing Market was valued at USD 32.6 billion in 2024 and is estimated to grow at a CAGR of 4.7% to reach USD 51.1 billion by 2034.
The expansion is driven by the rising prevalence of chronic and complex diseases such as cancer, Alzheimer's, and rare genetic disorders, which are creating demand for faster and more cost-effective therapeutic solutions. Drug repurposing enables quicker access to treatments, particularly for conditions where traditional R&D is limited due to low commercial incentives. By leveraging compounds with known safety and pharmacological profiles, repurposing bypasses early-stage trials, shortens development timelines, and accelerates regulatory approvals. This approach is particularly appealing to pharmaceutical firms seeking quicker returns on investment. Drug repurposing involves discovering new therapeutic applications for existing medications, including approved, discontinued, or abandoned drugs, reducing the overall time and cost of drug development while expanding treatment options across multiple disease areas.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $32.6 Billion |
| Forecast Value | $51.1 Billion |
| CAGR | 4.7% |
The small molecules segment held 67.5% share in 2024 and is expected to reach USD 33.8 billion by 2034, growing at a CAGR of 4.5%. Small molecules are ideal candidates for repurposing due to their established pharmacokinetics, safety data, and manufacturing processes. Existing clinical data can be leveraged to reduce the need for extensive trials, while regulatory pathways, such as the FDA's 505(b)(2), allow for faster approval by referencing prior evidence.
The oral drug segment generated USD 18.4 billion in 2024. Oral formulations are widely applicable across therapeutic areas, including oncology, metabolic, infectious, and CNS disorders. Their versatility and well-understood pharmacokinetics make them a preferred choice for repurposing, offering broad clinical utility and commercial appeal.
North America Drug Repurposing Market accounted for 48.2% share in 2024, led by the U.S., which benefits from a robust regulatory framework supporting drug repurposing. The FDA's 505(b)(2) pathway enables companies to reference existing safety and efficacy data for new indications, significantly reducing development time and costs. This regulatory flexibility has encouraged both pharmaceutical and biotech firms to invest heavily in repurposing strategies, fostering innovation and accelerating market growth.
Key players operating in the Global Drug Repurposing Market include Boehringer Ingelheim, Eli Lilly and Company, Amgen, AbbVie, Novartis, Pharnext, GlaxoSmithKline, Schwarz Pharma, Recursion Pharmaceuticals, Revolution Medicines, Cyclica, Pfizer, Melior Discovery, Sanofi, and Valence Discovery. Companies in the drug repurposing market are adopting multiple strategies to strengthen their market presence and expand their footprint. They are heavily investing in research and development to identify new therapeutic applications for existing drugs and optimize clinical trial efficiency. Strategic collaborations and partnerships with biotech firms, academic institutions, and research organizations help accelerate the discovery and validation of repurposed compounds.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/Country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Drug type trends
- 2.2.3 Therapeutic area trends
- 2.2.4 Route of administration trends
- 2.2.5 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factors affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of chronic and rare diseases
- 3.2.1.2 Cost and time efficiency of drug repurposing
- 3.2.1.3 Integration of AI-driven platforms
- 3.2.1.4 Unmet medical needs and drug shortages
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Lack of incentives for off-patent drugs
- 3.2.2.2 Liability and safety concerns
- 3.2.3 Market opportunities
- 3.2.3.1 Growing demand for cost-effective therapies
- 3.2.3.2 Expansion into rare and neglected diseases
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Future market trends
- 3.7 Pricing analysis
- 3.8 Clinical trial analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Small molecules
- 5.3 Biologics
Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Oncology
- 6.3 Neurology and CNS disorders
- 6.4 Infectious diseases
- 6.5 Cardiovascular diseases
- 6.6 Metabolic disorders
- 6.7 Other therapeutic areas
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Intravenous
- 7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Pharmaceutical and biopharmaceutical companies
- 8.3 Contract Research Organization (CROs)
- 8.4 Other end use
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 AbbVie
- 10.2 Amgen
- 10.3 Boehringer Ingelheim
- 10.4 Cyclica
- 10.5 Eli Lilly and Company
- 10.6 GlaxoSmithKline
- 10.7 Melior Discovery
- 10.8 Novartis
- 10.9 Pfizer
- 10.10 Pharnext
- 10.11 Recursion Pharmaceuticals
- 10.12 Revolution Medicines
- 10.13 Sanofi
- 10.14 Schwarz Pharma
- 10.15 Valence Discovery
